Phase 3 N=46 Effects of Pneumatic Vitreolysis on Vitreomacular Traction
Vitreomacular Traction
Primary: Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy — 78; 9 percentage of eyes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=220 Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Vitreomacular Adhesion Including Macular Hole
Primary: Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28 — 41.7; 6.2 Percentage (weighted across…
Phase 4 N=52 Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Vitreomacular Traction · Vitreomacular Adhesion
Primary: Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence…
N/A N=35 Effects of Pneumatic Vitreolysis on Macular Hole
Vitreomacular Traction (VMT) · Full-thickness Macular Holes (MH)
Primary: Proportion of Eyes With Macular Hole Closure of Inner Retinal Layers Without Rescue Vitrectomy — 10 Eyes
Phase 3 N=172 A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
Symptomatic Vitreomacular Adhesion
Primary: Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA) — 52.2; 1.8 percentage of subjects
Phase 3 N=326 Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28 — 25.3; 6.2 percentage of participants — p=<0.001
Phase 2 N=60 A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
Vitreomacular Traction
Primary: Proportion of Subjects With Total PVD at the First Day 14 Post-injection Visit (Vitreous Detachment to the Equator) as Determined by Masked Central Reading Center (CRC)…
Phase 3 N=326 Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28. — 27.9; 13.1 percentage of participants — p=0.003
Phase 4 N=468 Assessment of Patients Treated With JETREA® for Vitreomacular Traction
Vitreomacular Traction · Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Traction (VMT/VMA) at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain…
Phase 2 N=100 Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
Exudative Age-Related Macular Degeneration · Focal Vitreomacular Adhesion
Primary: Proportion of Subjects With Focal Vitreomacular Adhesion (VMA) Release by Day 28 — 24.3; 12.0 percentage of subjects — p=0.262
N/A N=87 Evaluation of Vitrectomy for Diabetic Macular Edema
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Visual Acuity — 52 Units on a scale
Phase 2 N=45 A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
Symptomatic Focal Vitreomacular Adhesion
Primary: Release of Vitreo Macular Adhesion (VMA) by Optical Coherence Tomography (OCT) — 4; 0 Participants
N/A N=19 Avastin for PDR (Proliferative Diabetic Retinopathy)
Retinal Detachment · Diabetic Retinopathy
Primary: The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction…
N/A N=78 Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes
Idiopathic Macular Hole
Primary: Visual Acuity (ETDRS Letters) — 74.9; 72.4; 72.2 Visual acuity in letters
Phase 3 N=381 Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
Phase 2 N=6 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Retinal Diseases · Telangiectasis
Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit
Phase 3 N=205 Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale
Phase 3 N=1,240 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Macular Degeneration
Primary: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.42; 95.62; 96.27; 95.56 Percentage of participants
Phase 1 N=40 Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
Intravitreal Bevacizumab Injection · Pars Plana Vitrectomy · Tractional Retinal Detachment
Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar
Phase 4 N=30 Transfoveal Micropulse Laser for Center Involving Diabetic Macular Edema
Diabetic Retinopathy · Macula Edema
Primary: Change in Central Retinal Thickness (CRT) — 384.62; 374; 349.15; 357.62 micrometer
Phase 3 N=406 Intravitreal Aflibercept Injection in Vision Impairment Due to DME
Diabetes Mellitus · Macular Edema
Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 3 N=1,217 Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
Macular Degeneration
Primary: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.4; 95.1; 95.9; 95.1 percentage of patients
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
N/A N=4 Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas
Scotoma, Central · Central Visual Impairment
Primary: Improvement in Eye-hand Coordination — 42.8; 45.4; 30.4; 71.0 Percentage
Phase 2 N=125 A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
Vitrectomy
Primary: Proportion of Patients Achieving Total Posterior Vitreous Detachment (PVD) Without Creation of an Anatomical Defect — 13.8; 18.2; 31.3; 10 percentage of participants…
N/A N=27 Micropulse for Suppression of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76
Phase 3 N=122 VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
Myopia, Pathological
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried…
Phase 3 N=189 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Macular Edema Secondary to Central Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score — 64; 9 percentage of participants — p=< 0.0001
Phase 3 N=177 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants…